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In April 2016, plans were announced for a dubious study
to examine whether the use of intrathecal bioactive pep-
tides, stem cells, lasers, and median nerve stimulation can
effectively reverse death by neurologic criteria (DNC) [1].
The possibility that DNC could be reversed was reported
in hundreds of articles around the world [2].
Unfortunately, this study has no scientific foundation
[3]. Biomedical science is based upon a quest for know-
ledge through observation and experimentation. Bioquark’s
study allegedly seeks to facilitate this quest. However, scien-
tific inquiry cannot be haphazard, and human studies must
be evidence-based and adhere to standards and regulations.
This project was approved internally at a hospital in
Rudrapur, India, but was not reviewed by the Indian
Council for Medical Research or any external scientific
or ethical committees [3]. Although the study is being
conducted in India and is not subject to American regu-
latory governance, Bioquark is based in the United States
and the trial is listed on the National Institute of Health’s
website, ClinicalTrials.gov. [1] Given the complete absence
of foundation for this study and it’s at best, ethically ques-
tionable, and at worst, outright unethical nature, this trial
would never be approved in the United States [3]. More-
over, Bioquark, who aims to “alter the regulatory state of
human tissues and organs,” has an blatant conflict of
interest in undertaking this activity [4].
By definition, DNC requires irreversible cessation of
all functions of the entire brain, including the brainstem.
As such, the proposal that DNC could be reversible is
self-contradictory. DNC is well-acknowledged by the
medical, legal, and ethical communities to constitute legal
death. The public, however, has a poor understanding
of DNC [5]. The suggestion that DNC could be reversed
provides families of brain dead patients a cruel, false hope
for recovery. This is especially so for families that believe
in reincarnation [3, 5].
Public understanding of DNC impacts organ and tissue
donation, legislation, public policy and clinical scenarios.
Knowledge about DNC is often based on stories in the
media, but articles about DNC frequently focus on dra-
matics and fail to educate the public [5].
Because this trial borders on quackery yet has been
well-publicized [2], it is the responsibility of the academic
community to facilitate a public dialogue about its scientific
and ethical shortcomings. Dead means dead. Proposing that
DNC may not be final openly challenges the medical-legal
definition of death, creates room for the exploitation of
grieving family and friends and falsely suggests science
where none exists [3].
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